Daewoong aims to reshape obesity market with patch
简介Daewoong Pharmaceutical said Monday the company will develop a microneedle-based obesity treatment d ...
Daewoong Pharmaceutical said Monday the company will develop a microneedle-based obesity treatment drug.
The South Korean pharmaceutical company aims to start a phase 1 clinical trial next year and launch the treatment in 2028.
Daewoong Pharmaceutical’s new obesity treatment will contain a synthetic peptide semaglutide, which is similar to glucagon-like peptide-1 (GLP-1), a hormone produced in the gut released in response to food to reduce appetite and the release of insulin.
The patch-type obesity treatment, measuring 1 square centimeter, will use drug-loaded dissolvable microneedles to penetrate the outer layer of the skin to deliver drug ingredients to the patient’s body. The company said patients will be able to easily administer the treatment and minimize injections-associated fears involving existing injection-type GLP-1 agonists.
“The patch-type obesity treatment will increase overall medication adherence of patients with obesity who have to take the treatment on a regular basis,” an official from Daewoong Pharmaceutical said. Daewoong Pharmaceutical said patients will need to use its patch-type obesity treatment just once a week.
Daewoong Pharmaceutical added the new treatment also aims to eliminate common side effects like skin swelling or lumps to improve the treatment experience.
For the development of the patch-type obesity treatment, Daewoong Pharmaceutical will also apply its own microneedle platform technology known as closed-packed aero-pressured microneedle (CLOPAM).
“While microneedles have been widely used in cosmetics, their application in medicine has been limited due to issues involving drug capacity and transdermal absorption. Daewoong Pharmaceutical’s CLOPAM technology is designed to ensure efficient drug delivery and minimize drug loss,” the official said.
Daewoong Pharmaceutical's microneedle platform technology will allow patients to store and use the treatment at room temperature, the official added.
Daewoong Pharmaceutical's microneedle platform has been developed by its research and development unit Daewoong Therapeutics. Daewoong Pharmaceutical has filed 23 patents in South Korea and registered six international patents for the microneedle technology. The company said it has received a proposal from a global pharmaceutical firm to develop other microneedle-based medications.
With the development of patch-type obesity treatment, Daewoong aims to enter the rapidly growing global obesity treatment market, it said. The global market for obesity treatments is expected to grow to 104 trillion won ($80 billion) by 2030, the firm said, quoting data from Morgan Stanley.
"Daewoong Pharmaceutical will push ahead with the development of the new patch-type obesity treatment for patients with unmet medical needs," Daewoong Pharmaceutical CEO Jeon Seung-ho said.
Meanwhile, Daewoong Pharmaceutical is also conducting studies to develop its new diabetes drug Enblo as a potential treatment for obesity.
Two major umbrella unions in South Korea on Tuesday criticized the government’s latest efforts to br ...
World-renowned architect Dominique Perrault unveiled details of an ongoing project at Seoul’s Gangna ...
Marking the first anniversary of the deadly Halloween crowd crush in Itaewon, some bereaved families ...
- New NZ minister takes oath in English and Korean
- Koreans well equipped to overcome global economic turmoil, says ex
- LG Electronics to bolster local strategies, B2B push to widen gap with Chinese rivals
- Han Kang's novel shortlisted for 2 prestigious French awards
- South Korea warns tit
- Seoul shares open sharply lower on US losses
Jeju's autonomy is model for Western Sahara: Morocco
Supreme Court dismisses Buseoksa's appeal in Bodhisattva statue ownership dispute
Prestige Biopharma eyes complete value chain
SK Pharmteco bets big on cell, gene therapy
Seoul shares start lower ahead of key rate decision
NiziU wins best pop video at MTV VMAJs
- [Today’s K
- 한·미 북핵 대응 전략 10년 만에 다시 쓴다
- Multicultural educator Min Byoung
- 홍익표, 조국 총선 출마설에 “조만간 뵙고 말씀 들을 것”
- SK On to furlough workers, cut production at US plant
- Korea, Japan airport operators hold first post
- Seoul shares down amid possible US government shutdown woes
- Redbreast 15 Year Old whiskey debuts in Korea
- 19 S. Koreans held captive in Myanmar freed: ministry
- Fifty Fifty’s Keena to attend 2023 BBMAs
- N. Korea diversifying cybercrimes amid drop in value of cryptocurrency: report
- 5 S. Koreans from Gaza arrived in Egypt via Rafah border: ministry
- 尹대통령 지지율 1%p 오른 34%…국민의힘 34% 민주당 33% [갤럽]
- Man wins W1.4b, putting to bed legal battle surrounding wife’s death
- NTOK Live+ to screen latest plays from UK, Netherlands
- Following an Israeli airstrike, crowded Gaza hospital struggles to treat wounded children
- From artisan to 'foreign laborer:' a French craftsman's take on Korea's construction scene
- S. Korea thanks countries near Gaza for assisting in evacuation of S. Korean family
- Quake shakes northwest Nepal, killing at least 128 and injuring dozens
- [Today’s K
- Foreign exchange reserves fall for third consecutive month
- Hana Bank to offer W100b in support for small business owners
- Seoul shares up for 3rd session on Fed's rate freeze
- [New in Korean] Millionaire dog sponsors human artist in Yun Ko
- [New in Korean] 'The path to happiness is forgiveness,' says Korea's first million
- N. Korea vows military action after US missile test
- South Korea lining up banks to help finance $22 billion arms sale to Poland
- S. Korea to set up task force to put rising prices under control
- Blinken redoubles calls for humanitarian pause in Israel
- Gimjang tours make kimchi